Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria
- Insulin-naïve type 2 diabetes mellitus
- Type 2 diabetes mellitus diagnosed for at least 1 year
- Treated with at least one OAD (Metformin [daily dose of at least 1000mg], Sulfonylurea, glinides or alpha-glucosidase inhibitor) at stable dose for at least 3 months.
- HbA1c > or = 7.0% and < or = 10.5%
- BMI < 40 kg/m²
- Ability and willingness to perform plasma glucose monitoring using the sponsor-provided glucose meter and patient diary at home
- Informed consent obtained in writing at enrolment into the study
- Willingness and ability to comply with the study protocol
Exclusion criteria:
- Treatment with GLP-1 agonists or with DPP-IV inhibitors in the 3 months prior to study entry
- Treatment with TZD as monotherapy
- Diabetes mellitus other than Type 2 (e.g. secondary to pancreatic disorders, drugs or chemical agents intake...)
- Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry)
- Impaired renal function: serum creatinine > or =1.5 mg/dL (> or = 133µmol/L) or > or = 1.4 mg/dL (> or = 124 µmol/L) in men and women, respectively
- History of sensitivity to the study drugs or to drugs with a similar chemical structure
- Impaired hepatic function (ALT and/or AST > 3 x upper limit of normal range)
- Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),
- Treatment with systemic corticosteroids within the 3 months prior to study entry or likelihood of requiring treatments during the study which are not permitted.
- Treatment with an investigational product in the 30 days prior to visit 1
- Alcohol or drug abuse in the last year
- Presence of any condition (medical, psychological, social or geographical), current or anticipated that the Investigator feels would compromise the patient's safety or limit the patient successful participation in the study (including night shift worker)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 076-001
- Investigational Site Number 076-006
- Investigational Site Number 076-005
- Investigational Site Number 076-007
- Investigational Site Number 076-004
- Investigational Site Number 076-003
- Investigational Site Number 076-002
- Investigational Site Number 203003
- Investigational Site Number 203008
- Investigational Site Number 203011
- Investigational Site Number 203001
- Investigational Site Number 203006
- Investigational Site Number 203002
- Investigational Site Number 203010
- Investigational Site Number 203009
- Investigational Site Number 203004
- Investigational Site Number 203005
- Investigational Site Number 203007
- Investigational Site Number 818001
- Investigational Site Number 250-002
- Investigational Site Number 250-001
- Investigational Site Number 250-005
- Investigational Site Number 250-004
- Investigational Site Number 250-003
- Investigational Site Number 250-006
- Investigational Site Number 380001
- Investigational Site Number 410005
- Investigational Site Number 410002
- Investigational Site Number 410006
- Investigational Site Number 410001
- Investigational Site Number 410003
- Investigational Site Number 410004
- Investigational Site Number 414001
- Investigational Site Number 484003
- Investigational Site Number 484005
- Investigational Site Number 484001
- Investigational Site Number 484008
- Investigational Site Number 484009
- Investigational Site Number 484002
- Investigational Site Number 528006
- Investigational Site Number 528005
- Investigational Site Number 528001
- Investigational Site Number 528002
- Investigational Site Number 528004
- Investigational Site Number 528003
- Investigational Site Number 616004
- Investigational Site Number 616003
- Investigational Site Number 616002
- Investigational Site Number 616001
- Investigational Site Number 642001
- Investigational Site Number 642002
- Investigational Site Number 642009
- Investigational Site Number 642003
- Investigational Site Number 642005
- Investigational Site Number 642010
- Investigational Site Number 642011
- Investigational Site Number 642007
- Investigational Site Number 642004
- Investigational Site Number 642008
- Investigational Site Number 642012
- Investigational Site Number 643-001
- Investigational Site Number 643-006
- Investigational Site Number 643-005
- Investigational Site Number 643-002
- Investigational Site Number 643-003
- Investigational Site Number 643-004
- Investigational Site Number 643-007
- Investigational Site Number 703005
- Investigational Site Number 703003
- Investigational Site Number 703007
- Investigational Site Number 703004
- Investigational Site Number 703006
- Investigational Site Number 703002
- Investigational Site Number 703008
- Investigational Site Number 703001
- Investigational Site Number 752004
- Investigational Site Number 752002
- Investigational Site Number 752003
- Investigational Site Number 752001
- Investigational Site Number 756001
- Investigational Site Number 764004
- Investigational Site Number 764001
- Investigational Site Number 764002
- Investigational Site Number 764003
- Investigational Site Number 764006
- Investigational Site Number 764005
- Investigational Site Number 784-001
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
Before randomization (common with arm 2): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose
Before randomization (common with arm 1): 2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride After randomization: 36 weeks of study treatment phase: NPH + OAD(s) at stable dose